Insight Molecular Diagnostics Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
IMDX$2.50+0.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(In thousands, except per share data)
| Years EndedDecember 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Net revenue | $4,055 | $1,881 |
| Cost of revenues | 1,750 | 1,053 |
| Cost of revenues – amortization of acquired intangibles | 7 | 88 |
| Gross profit | 2,298 | 740 |
| Operating expenses: | ||
| Research and development | 15,900 | 9,839 |
| Sales and marketing | 6,343 | 3,944 |
| General and administrative | 10,633 | 10,204 |
| Change in fair value of contingent consideration | 5,946 | (4,275) |
| Impairment losses | 14,600 | 41,900 |
| Impairment loss on held for sale assets | — | 169 |
| Total operating expenses | 53,422 | 61,781 |
| Loss from operations | (51,124) | (61,041) |
| Other (expenses) income: | ||
| Interest expense | (109) | (84) |
| Other income, net | 1,011 | 462 |
| Total other income, net | 902 | 378 |
| Loss before income taxes | (50,222) | (60,663) |
| Income taxes | — | — |
| Net loss | $(50,222) | $(60,663) |
| Net loss per share (Note 2): | ||
| Net loss attributable to common stockholders - basic and diluted | $(50,222) | $(60,926) |
| Net loss attributable to common stockholders per share - basic and diluted | $(1.65) | $(4.66) |
| Weighted average shares outstanding - basic and diluted | 30,476 | 13,071 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.